Receptor Biologix Raises $33.6 Million to Fund Lead Product Candidate

Receptor Biologix a biopharmaceutical company focused on developing newly discovered protein therapeutics to treat cancer, autoimmune, metabolic and other diseases, today announced it raised $33.6 million dollars in a Series A financing. Key venture investors included Skyline Ventures (who led the syndicate), Domain Associates, Essex Woodlands Health Ventures, MedImmune Ventures, Takeda Research Investment a wholly owned subsidiary of Takeda America Holdings and Northwest Technology Ventures.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/04-28-2005/0003491111&EDATE=)